Recent discussions on X about aTyr Pharma, Inc. (ATYR) have been intensely focused on the company's significant stock price drop following the failure of its Phase 3 trial for efzofitimod, a drug targeting pulmonary sarcoidosis. Many users have expressed shock at the over 80% plunge in stock value since mid-September, with some cautioning against the inherent risks of biotech investments. The conversation has sparked debates about the future viability of the company amidst this setback.
However, a sliver of optimism has emerged in recent posts on X, as some users point to a slow rebound in stock price and insider buying activity, including a notable purchase of shares by a director earlier this week. There's speculation about potential short covering and predictions of a near-term rise in stock value, though skepticism remains high given the trial miss. This mix of caution and cautious hope keeps the dialogue around ATYR dynamic and closely watched.
Note: This discussion summary was generated from an AI condensation of post data.
aTyr Pharma, Inc. Insider Trading Activity
aTyr Pharma, Inc. insiders have traded $ATYR stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ATYR stock by insiders over the last 6 months:
- PAUL SCHIMMEL has made 2 purchases buying 1,000,000 shares for an estimated $911,801 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
aTyr Pharma, Inc. Analyst Ratings
Wall Street analysts have issued reports on $ATYR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 08/22/2025
To track analyst ratings and price targets for aTyr Pharma, Inc., check out Quiver Quantitative's $ATYR forecast page.
aTyr Pharma, Inc. Price Targets
Multiple analysts have issued price targets for $ATYR recently. We have seen 4 analysts offer price targets for $ATYR in the last 6 months, with a median target of $9.25.
Here are some recent targets:
- Derek Archila from Wells Fargo set a target price of $1.0 on 09/16/2025
- Brian Abrahams from RBC Capital set a target price of $1.5 on 09/16/2025
- Roger Song from Jefferies set a target price of $17.0 on 08/22/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $35.0 on 06/04/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
